To recover your password please fill in your email address
Please fill in below form to create an account with us
A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women with BRCA 1/2 Mutations
See ANZCTR for full trial details >
|
Trial Summary: |
To determine whether taking Acetylsalicylic Acid (aspirin) may help to prevent ovarian cancer in women with a high risk gene mutation in BRCA1 or BRCA2, who plan to have the standard risk-reducing surgery. |
|
Supported By: |
CCTG with funding from NHMRC |
|
Eligibility: |
Patients at high risk of ovarian cancer, who are scheduled in the next 6 months to 2 years to have surgery to reduce their risk of getting ovarian cancer by removing the fallopian tubes and ovaries. |
|
Registration ID: |
ACTRN12619000520134 |
|
Participation: |
Australia, Canada |
|
Australian Lead Group: |
ANZGOG |
|
Status: |
In follow up |
|
Activation Date: |
9/12/2019 |
|
Chairs: |
Prof Kelly-Anne Phillips |
|
Contact: |